OBJECTIVE: To clarify the role of novel mutations selected by treatment with efavirenz or nevirapine, and investigate the influence of HIV-1 subtype on nonnucleoside reverse transcriptase inhibitor (nNRTI) resistance pathways. DESIGN: By finding direct dependencies between treatment-selected mutations, the involvement of these mutations as minor or major resistance mutations against efavirenz, nevirapine, or coadministrated nucleoside analogue reverse transcriptase inhibitors (NRTIs) is hypothesized. In addition, direct dependencies were investigated between treatment-selected mutations and polymorphisms, some of which are linked with subtype, and between NRTI and nNRTI resistance pathways. METHODS: Sequences from a large collaborative database of various subtypes were jointly analyzed to detect mutations selected by treatment. Using Bayesian network learning, direct dependencies were investigated between treatment-selected mutations, NRTI and nNRTI treatment history, and known NRTI resistance mutations. RESULTS: Several novel minor resistance mutations were found: 28K and 196R (for resistance against efavirenz), 101H and 138Q (nevirapine), and 31L (lamivudine). Robust interactions between NRTI mutations (65R, 74V, 75I/M, and 184V) and nNRTI resistance mutations (100I, 181C, 190E and 230L) may affect resistance development to particular treatment combinations. For example, an interaction between 65R and 181C predicts that the nevirapine and tenofovir and lamivudine/emtricitabine combination should be more prone to failure than efavirenz and tenofovir and lamivudine/emtricitabine. CONCLUSION: Bayesian networks were helpful in untangling the selection of mutations by NRTI versus nNRTI treatment, and in discovering interactions between resistance mutations within and between these two classes of inhibitors.
OBJECTIVE: To clarify the role of novel mutations selected by treatment with efavirenz or nevirapine, and investigate the influence of HIV-1 subtype on nonnucleoside reverse transcriptase inhibitor (nNRTI) resistance pathways. DESIGN: By finding direct dependencies between treatment-selected mutations, the involvement of these mutations as minor or major resistance mutations against efavirenz, nevirapine, or coadministrated nucleoside analogue reverse transcriptase inhibitors (NRTIs) is hypothesized. In addition, direct dependencies were investigated between treatment-selected mutations and polymorphisms, some of which are linked with subtype, and between NRTI and nNRTI resistance pathways. METHODS: Sequences from a large collaborative database of various subtypes were jointly analyzed to detect mutations selected by treatment. Using Bayesian network learning, direct dependencies were investigated between treatment-selected mutations, NRTI and nNRTI treatment history, and known NRTI resistance mutations. RESULTS: Several novel minor resistance mutations were found: 28K and 196R (for resistance against efavirenz), 101H and 138Q (nevirapine), and 31L (lamivudine). Robust interactions between NRTI mutations (65R, 74V, 75I/M, and 184V) and nNRTI resistance mutations (100I, 181C, 190E and 230L) may affect resistance development to particular treatment combinations. For example, an interaction between 65R and 181C predicts that the nevirapine and tenofovir and lamivudine/emtricitabine combination should be more prone to failure than efavirenz and tenofovir and lamivudine/emtricitabine. CONCLUSION: Bayesian networks were helpful in untangling the selection of mutations by NRTI versus nNRTI treatment, and in discovering interactions between resistance mutations within and between these two classes of inhibitors.
Authors: Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme Journal: Bioinformatics Date: 2005-08-02 Impact factor: 6.937
Authors: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2007 Aug-Sep
Authors: Zehava Grossman; Valery Istomin; Diana Averbuch; Margalit Lorber; Klaris Risenberg; Itzchak Levi; Michael Chowers; Michael Burke; Nimrod Bar Yaacov; Jonathan M Schapiro Journal: AIDS Date: 2004-04-09 Impact factor: 4.177
Authors: Jason H Karnes; Sara Van Driest; Erica A Bowton; Peter E Weeke; Jonathan D Mosley; Josh F Peterson; Joshua C Denny; Dan M Roden Journal: Wiley Interdiscip Rev Syst Biol Med Date: 2013-12-06
Authors: Glenn Lawyer; André Altmann; Alexander Thielen; Maurizio Zazzi; Anders Sönnerborg; Thomas Lengauer Journal: AIDS Res Ther Date: 2011-07-27 Impact factor: 2.250
Authors: Susana Posada-Céspedes; Gert Van Zyl; Hesam Montazeri; Jack Kuipers; Soo-Yon Rhee; Roger Kouyos; Huldrych F Günthard; Niko Beerenwinkel Journal: PLoS Comput Biol Date: 2021-09-07 Impact factor: 4.475